Chemokine 12 (CXCL12), also known as stromal cell derived factor-1 (SDF-1) and a member of the CXC chemokine subfamily, is ubiquitously expressed in many tissues and cell types. It interacts specifically with the ligand for the transmembrane G protein-coupled receptors CXCR4 and CXCR7. The CXCL12/CXCR4 axis takes part in a series of physiological, biochemical, and pathological process, such as inflammation and leukocyte trafficking, cancer-induced bone pain, and postsurgical pain, and also is a key factor in the cross-talking between tumor cells and their microenvironment. Aberrant overexpression of CXCR4 is critical for tumor survival, proliferation, angiogenesis, homing and metastasis. In this review, we summarized the role of CXCL12/CXCR4 in cancer, CXCR4 inhibitors under clinical study, and natural product CXCR4 antagonists. In conclusion, the CXCL12/CXCR4 signaling is important for tumor development and targeting the pathway might represent an effective approach to developing novel therapy in cancer treatment.
Animals ; Antineoplastic Agents ; chemical synthesis ; chemistry ; pharmacology ; Biological Products ; chemistry ; pharmacology ; Chemokine CXCL12 ; genetics ; metabolism ; Humans ; Molecular Targeted Therapy ; Neoplasms ; drug therapy ; genetics ; metabolism ; Receptors, CXCR4 ; antagonists & inhibitors ; genetics ; metabolism

OBJECTIVETo study the expression of HIF-1alpha and SDF-1/CXCR4 in repopulating H22 tumor tissue and the mechanism of angiogenesis of polypeptide extract from scorpion venom (PESV) during chemotherapy treatment.

METHODThe expression of HIF-1alpha and SDF-1/CXCR4 in H22 tumor tissue was monitored by immunohistochemistry, and the expression level was determined by Qwin V3 image analyzing software. The correlation between HIF-1alpha and SDF-1 was analyzed. SDF-1 content was detected by ELISA.

RESULTHIF-1alpha expression was found no difference in model group between 14 d and 21 d, and up-regulated in 28 d. There was no change of HIF-1alpha expression was observed in low-dose PESV group. In high-dose PESV group, the level of HIF-1alpha expression was high in 14 d and low in 21 d. ELISA detecting showed SDF-1 content increased slowly from 14 d to 21 d, highly from 21 d to 28 d. But in high-dose PESV groups, the content increased slowly all the time. The immunohitochemistry method got the same result with ELISA. Correlation analysis showed r = 0.805. CXCR4 expression down-regulated in two PESV treated groups, and no difference was found between these two groups.

CONCLUSIONHIF-1alpha and SDF-1 participated in VEGF expression and angiogenesis in tumor tissue during chemotherapy, while PESV could inhibit the expression of HIF-1alpha and SDF-I.

Animals ; Cell Line, Tumor ; Chemokine CXCL12 ; drug effects ; metabolism ; Down-Regulation ; drug effects ; Hypoxia-Inducible Factor 1, alpha Subunit ; drug effects ; metabolism ; Mice ; Peptides ; pharmacology ; Receptors, CXCR4 ; drug effects ; metabolism ; Scorpion Venoms ; chemistry ; pharmacology ; Scorpions ; chemistry ; Time Factors

CXC chemokine receptor 4 (CXCR4), which binds the stromal cell-derived factor-1 (SDF-1), has been shown to play a critical role in mobilizing the bone marrow (BM)-derived stem cells and inflammatory cells. We studied the effects of AMD3100, CXCR4 antagonist, on a murine bleomycin-induced pulmonary fibrosis model. Treatment of mice with AMD3100 in bleomycin-treated mice resulted in the decrease of SDF-1 in bronchoalveolar lavage (BAL) fluids at an early stage and was followed by the decrease of fibrocytes in the lung. AMD3100 treatment decreased the SDF-1 mRNA expression, fibrocyte numbers in the lung at an early stage (day 3) and CXCR4 expression at the later stage (day 7 and 21) after bleomycin injury. The collagen content and pulmonary fibrosis were significantly attenuated by AMD3100 treatment in later stage of bleomycin injury. AMD3100 treatment also decreased the murine mesenchymal and hematopoietic stem cell chemotaxis when either in the stimulation with bleomycin treated lung lysates or SDF-1 in vitro. In BM stem cell experiments, the phosphorylation of p38 MAPK which was induced by SDF-1 was significantly blocked by addition of AMD3100. Our data suggest that AMD3100 might be effective in preventing the pulmonary fibrosis by inhibiting the fibrocyte mobilization to the injured lung via blocking the SDF-1/CXCR4 axis.
Animals ; *Bleomycin ; Bronchoalveolar Lavage Fluid/chemistry ; Cell Movement/drug effects ; Cells, Cultured ; Chemokine CXCL12/chemistry/metabolism ; Cytoprotection/drug effects ; Down-Regulation/drug effects ; Drug Evaluation, Preclinical ; Female ; Heterocyclic Compounds/pharmacology/*therapeutic use ; Lung/drug effects/metabolism/pathology ; Mice ; Mice, Inbred C57BL ; Pulmonary Fibrosis/*chemically induced/*prevention & control ; Receptors, CXCR4/*antagonists & inhibitors/metabolism

OBJECTIVETo investigate the anti-HIV effects of ampelopsin and its interaction with HIV-1 coreceptor CXCR4.

METHODSThrough anti-virus experiments in vitro, the inhibitory effect of ampelopsin on HIV-1 infection was verified. Chemotaxis assay was performed to show the ability to induce PBMCs migration by ampelopsin, RANTES and SDF-1alpha. Fluorescence labelling monoclonal antibody was utilized to observe the interaction of ampelopsin and CXCR4. Mice immunosuppressant model was also established to detail the role ampelopsin played in regulating cellular immunological functions.

RESULTSAmpelopsin could protect sensitive cells against HIV-1 infection and dramatically reduce HIV-1 antigen P24 expression. HIV-1SF33 attaching to MT-4 cells was interfered by ampelopsin, and the EC50 was 0.175 mg/mL for cellular protection and 0.024 mg/mL for P24 inhibition. At co-cultivating phase, EC50 was 0.229 mg/mL and 0.197 mg/mL respectively. Furthermore, the EC50 was 0.179 mg/mL and 0.348 mg/mL in acute infection. Human PBMCs migration was induced after being challenged with ampelopsin or chemokines, and synergistic action was observed during co-treatment. Ampelopsin alone resulted in maximal chemotaxis at 1 mg/mL. HIV-1 co-receptor CXCR4 on the surface of PBMCs was decreased by internalization, which indicated the effect of ampelopsin on CXCR4. About 70% CXCR4 was reduced by ampelopsin at 1 mg/mL. Ampelopsin also augmented cellular immunological functions in immunosuppressive mice.

CONCLUSIONAmpelopsin displays a strong inhibitive role during HIV-1 absorption, incubation and acute infection. These results are coincident with its immune enhancement.

Ampelopsis ; chemistry ; Animals ; Anti-HIV Agents ; pharmacology ; Cell Line ; Chemokine CCL5 ; pharmacology ; Chemokine CXCL12 ; Chemokines, CXC ; pharmacology ; Chemotaxis, Leukocyte ; Down-Regulation ; Drugs, Chinese Herbal ; Flavonoids ; economics ; isolation & purification ; pharmacology ; HIV Infections ; virology ; HIV-1 ; drug effects ; metabolism ; pathogenicity ; Humans ; Interleukin-2 ; biosynthesis ; Leukocytes, Mononuclear ; drug effects ; Mice ; Mice, Inbred BALB C ; Models, Animal ; Plant Roots ; chemistry ; Receptors, CXCR4 ; antagonists & inhibitors ; drug effects ; Spleen ; immunology ; T-Lymphocytes ; immunology